Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The T-PLL Channel

Explore the latest updates and expert interviews

Welcome to The T-cell prolymphocytic leukemia (T-PLL) Channel

VJHemOnc covers exciting and topical research directly from the experts at major international congresses so that you can stay informed.

Catch up on updates in T-PLL by watching our video interviews with leading experts.

Long-term outcomes of alloSCT for T-cell prolymphocytic leukemia 2:07
Long-term outcomes of alloSCT for T-cell prolymphocytic leukemia
Olivier Tournilhac • 8 Dec 2024
A Phase Ib trial investigating the combination of ruxolitinib and duvelisib in R/R T-cell lymphoma 1:52
A Phase Ib trial investigating the combination of ruxolitinib and duvelisib in R/R T-cell lymphoma
Alison Moskowitz • 9 Dec 2024
The current treatment landscape for patients with T-cell prolymphocytic leukemia 1:23
The current treatment landscape for patients with T-cell prolymphocytic leukemia
Dima El-Sharkawi • 28 Apr 2024
Challenges with diagnosing mature T-cell leukemias 2:21
Challenges with diagnosing mature T-cell leukemias
Dima El-Sharkawi • 24 Apr 2023
Pathobiology & treatment of T-PLL 3:55
Pathobiology & treatment of T-PLL
Marco Herling • 12 Jun 2022
Itacitinib plus alemtuzumab for patients with T-PLL 2:58
Itacitinib plus alemtuzumab for patients with T-PLL
Tapan Kadia • 10 Jun 2022
PET scans in NHL 1:55
PET scans in NHL
Sally Barrington • 9 Jun 2021
Ruxolitinib plus venetoclax for T-PLL: rationale and findings 1:26
Ruxolitinib plus venetoclax for T-PLL: rationale and findings
Charles Herbaux • 25 May 2021
The biology of T-ALL 2:42
The biology of T-ALL
Scott Armstrong • 10 May 2021
Should AMTL be defined as a distinct diagnostic entity? 1:40
Should AMTL be defined as a distinct diagnostic entity?
Jonathan Bond • 18 Jun 2020
Acute leukemias at the T-lymphoid/myeloid interface 12:51
Acute leukemias at the T-lymphoid/myeloid interface
Jonathan Bond • 18 Jun 2020
Off-the-shelf CAR-T for T-cell malignancies: UCART3 1:28
Off-the-shelf CAR-T for T-cell malignancies: UCART3
John DiPersio • 4 Mar 2019
The diagnosis of early T-cell precursor (ETP) ALL 1:25
The diagnosis of early T-cell precursor (ETP) ALL
Bijal Shah • 17 Feb 2018
The evolving genomic landscape of ALL: molecular genetics, profiling and classification 11:57
The evolving genomic landscape of ALL: molecular genetics, profiling and classification
Anjali Advani et al. • 17 Feb 2018
Recent subtypes of ALL: Ph-like ALL and ETP ALL 10:31
Recent subtypes of ALL: Ph-like ALL and ETP ALL
Anjali Advani et al. • 17 Feb 2018
Phase III study shows tailored treatment improves response in T-lymphocytic leukemia 5:38
Phase III study shows tailored treatment improves response in T-lymphocytic leukemia
Brent Wood • 5 Dec 2014

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals